Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$534M |
| 2 |
Amazon
AMZN
|
+$399M |
| 3 |
Abbott
ABT
|
+$381M |
| 4 |
Adobe
ADBE
|
+$353M |
| 5 |
Oracle
ORCL
|
+$261M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sherwin-Williams
SHW
|
+$407M |
| 2 |
Bank of America
BAC
|
+$368M |
| 3 |
TE Connectivity
TEL
|
+$366M |
| 4 |
Goldman Sachs
GS
|
+$302M |
| 5 |
Atlassian
TEAM
|
+$301M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.57% |
| 2 | Healthcare | 19.51% |
| 3 | Consumer Discretionary | 9.79% |
| 4 | Industrials | 9.79% |
| 5 | Financials | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Biomea Fusion
BMEA
$88.2M
| $25M | 0.01% |
1,718,245
-1,259,236
| -42% | -$15.3M |
|
502
Bristol-Myers Squibb
BMY
$129B
| $24.9M | 0.01% |
484,804
-52,839
| -10% | -$2.77M |
|
503
Teradyne
TER
$50B
| $24.8M | 0.01% |
228,481
+41,453
| +22% | +$3.93M |
|
|
DAWN
504
DELISTED
Day One Biopharmaceuticals
DAWN
| $24.8M | 0.01% |
1,696,103
+874,650
| +106% | +$10.6M |
|
505
Evertec
EVTC
$1.97B
| $24.8M | 0.01% |
604,809
-191,861
| -24% | -$7.05M |
|
506
JPMorgan BetaBuilders Developed Asia Pacific-ex Japan ETF
BBAX
$6.66B
| $24.7M | 0.01% |
498,420
+363,125
| +268% | +$16.7M |
|
507
RenaissanceRe
RNR
$13.8B
| $24.6M | 0.01% |
125,462
-10,353
| -8% | -$2.15M |
|
508
Blackrock
BLK
$167B
| $24.6M | 0.01% |
30,243
+6,674
| +28% | +$4.66M |
|
509
RTX Corp
RTX
$290B
| $24.4M | 0.01% |
290,360
+56,873
| +24% | +$4.5M |
|
|
AGTI
510
DELISTED
Agiliti Inc
AGTI
| $24.3M | 0.01% |
3,073,520
-704
| -0% | -$4.77K |
|
511
Novanta
NOVT
$4.91B
| $24.3M | 0.01% |
144,300
-39,654
| -22% | -$5.78M |
|
512
Westlake Corp
WLK
$9.26B
| $24.1M | 0.01% |
172,439
-33,175
| -16% | -$4.21M |
|
513
Ferrari
RACE
$67.8B
| $23.9M | 0.01% |
70,528
-28,249
| -29% | -$9.43M |
|
514
SK Telecom
SKM
$11.4B
| $23.9M | 0.01% |
1,114,601
-141,604
| -11% | -$3M |
|
515
Union Pacific
UNP
$174B
| $23.6M | 0.01% |
96,011
+11,397
| +13% | +$2.51M |
|
516
First Busey Corp
BUSE
$2.6B
| $23.5M | 0.01% |
947,125
+100,150
| +12% | +$2.14M |
|
|
JLQD
517
Janus Henderson Corporate Bond ETF
JLQD
$14.2M
| $23.2M | 0.01% |
553,763
-3,488
| -0.6% | -$139K |
|
518
Burford Capital
BUR
$914M
| $23.2M | 0.01% |
1,497,115
-182,187
| -11% | -$2.44M |
|
519
Vertex
VERX
$2.16B
| $23.1M | 0.01% |
859,267
+3,110
| +0.4% | +$79.7K |
|
|
HCP
520
DELISTED
HashiCorp, Inc. Class A Common Stock
HCP
| $22.9M | 0.01% |
970,047
+931,210
| +2,398% | +$20.2M |
|
521
Agnico Eagle Mines
AEM
$72.2B
| $22.9M | 0.01% |
417,226
+46,411
| +13% | +$2.32M |
|
522
Enpro
NPO
$6.26B
| $22.7M | 0.01% |
145,086
+38,477
| +36% | +$4.98M |
|
523
AerSale
ASLE
$291M
| $22.7M | 0.01% |
1,789,818
+89,699
| +5% | +$1.3M |
|
524
Patria Investments
PAX
$1.72B
| $22.6M | 0.01% |
1,454,720
-206
| -0% | -$2.92K |
|
525
Repay Holdings
RPAY
$335M
| $22.5M | 0.01% |
2,638,456
+655,533
| +33% | +$4.62M |
|
Similar funds
Janus Henderson Group's Q4 2023 Portfolio in Review
As of Q4 2023, Janus Henderson Group held 2,657 positions worth $168B, up 9.8% from $153B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Janus Henderson Group's Q4 2023 filing shows 98 new, 642 increased, 1,760 reduced and 111 closed positions. Its largest new stake was Veralto: 2,881,576 shares worth $237M. The largest sale was Sherwin-Williams, an estimated $407M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q4 2023 buy was Veralto: 2,881,576 shares worth $237M.
- Janus Henderson Group added most to Eli Lilly in Q4 2023, an estimated $534M increase.
- Janus Henderson Group's biggest Q4 2023 reduction was Sherwin-Williams, cutting an estimated $407M.
- Janus Henderson Group fully exited National Instruments Corp in Q4 2023, selling an estimated $243M.
- Janus Henderson Group's ten largest holdings make up 27% of its $168B portfolio in Q4 2023.
- Janus Henderson Group opened 98 new positions and closed 111 in Q4 2023.
- Janus Henderson Group's portfolio value rose 9.8% quarter-over-quarter to $168B.
Based on Janus Henderson Group's 13F filing for Q4 2023, filed 14 Feb 2024.